Education
About Us
Working with TipRanks
Follow Us
Moderna (DE:0QF)
XETRA:0QF
0QF Stock Chart & Stats
Day’s Range― - ―
52-Week Range€20.59 - €156.54
Previous CloseN/A
Volume96.78K
Average Volume (3M)18.30K
Market Cap
$8.33B
Enterprise Value€5.71B
Total Cash (Recent Filing)$1.62B
Total Debt (Recent Filing)$745.00M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Jul 31, 2025EPS Estimate
-2.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.23
Shares Outstanding386,741,820
10 Day Avg. Volume13,103
30 Day Avg. Volume18,298
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.79
Forecast
1Y Price Target
$41.19Price Target Upside91.41% Upside
Rating ConsensusHold
Number of Analyst Covering20
---
Moderna News
PremiumMarket News
SPY ETF News, 5/7/2025
PremiumMarket News
VOO ETF News, 5/2/2025
---
Bulls Say, Bears Say
Bulls Say
Cost ManagementModerna is accelerating its cost-saving programme with lowered cost guidance and additional savings targets.
Oncology PipelineShifting focus increasingly towards oncology with additional studies for intismeran and Checkpoint AIM-T highlights the increasing need for future non-respiratory revenues.
Revenue GuidanceThe company reiterated its 2025 revenue guidance of $1.5-2.5B, which it still expects to be heavily weighted to the second half due to the seasonality of the respiratory vaccine business.
Bears Say
Product SalesFirst-quarter product sales were $86 million, which fell short of the consensus estimate at $106 million.
Regulatory RiskModerna faces regulatory risk with three late-stage respiratory vaccine submissions under review by the FDA.
Vaccine Market ChallengesIn general, the respiratory vaccine franchise is facing competitive and commercial headwinds.
---
Options Prices
Currently, No data available
---
Ownership Overview
18.59% Insiders
19.67%
Mutual Funds
2.06% Other Institutional Investors
37.69% Public Companies and
Individual Investors
0QF FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was €20.59 and its highest was €156.54 in the past 12 months.
What is Moderna’s market cap?
Moderna’s market cap is $8.33B.
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is Jul 31, 2025 which is in 83 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on May 01, 2025. The company reported -€2.231 earnings per share for the quarter, beating the consensus estimate of -€2.759 by €0.528.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Undervalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -2.64.
How many shares outstanding does Moderna have?
Moderna has 386,741,820 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -€2.231 in its last earnings report, beating expectations of -€2.759. Following the earnings report the stock price went up 7.197%.
Which hedge fund is a major shareholder of Moderna?
Currently, no hedge funds are holding shares in DE:0QF
---
Moderna Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$41.19 (91.41% Upside)
$41.19 (91.41% Upside)
Blogger Sentiment
Bullish
DE:0QF Sentiment 65%
Sector Average 71%
Sector Average 71%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-79.99%
12-Months-Change
Fundamentals
Return on Equity
-29.34%
Trailing 12-Months
Asset Growth
-24.06%
Trailing 12-Months
Company Description
Moderna
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
---
0QF Company Deck
---
0QF Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Moderna has made significant progress in cost reduction and market expansion, particularly in the oncology and international vaccine markets. However, the company still faces challenges with declining revenues, significant net losses, and extended regulatory review timelines for key products.Read More>---
0QF Revenue Breakdown
55.16% U.S.
26.36% Rest of World
18.48% Europe
---
0QF Stock 12 Month Forecast
Average Price Target
€41.19
▲(91.41% Upside)
Technical Analysis
---